Western blot shows lysates of HepG2 human hepatocellular carcinoma cell line and NTera-2 human testicular embryonic carcinoma cell line. PVDF membrane was probed with 1 µg/mL of Human PERK Antigen Affinity‑purified ...read more
Genetic Strategies: Western blot shows lysates of HeLa human cervical epithelial carcinoma parental cell line and PERK knockout HeLa cell line (KO). PVDF membrane was probed with 1 µg/mL of Goat ...read more
PERK, a type 1 ER membrane kinase, mediates eIF2 alpha phosphorylation at Ser51 during the UPR (unfolded protein response). Protein synthesis is inhibited, thereby reducing the burden of protein substrate for the ER folding and degradation mechanism. Phosphorylation of eIF2 alpha also selectively promotes the expression of UPR target genes such as Chop and BiP. PERK may also play a role in tumor cell adaptation to hypoxic stress by regulating the translation of angiogenic factors necessary for the development of functional microvessels. Mutations in PERK are responsible for the rare autosomal-recessive disorder, WRS (Wolcott-Rallison syndrome).
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our PERK Antibody [Unconjugated] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.